Sai Life Sciences: Jefferies' Top CRDMO Pick with 29% Upside

Jefferies Endorses Sai Life Sciences as Top CRDMO Pick

Jefferies has identified Sai Life Sciences Ltd. as its leading choice in the contract research, development, and manufacturing organisation (CRDMO) sector. The brokerage reiterated its 'Buy' rating on the stock, increasing the price target to ₹1,300, which suggests a potential upside of 29 percent from current levels. This optimistic outlook is underpinned by the company's integrated business model, robust growth prospects, and a healthy project pipeline.

In line with its positive stance, Jefferies has also revised its financial estimates for the company. The firm raised its sales forecast for the Financial Year 2028 (FY28) by 3 percent and its earnings per share (EPS) estimate by 5 percent, signaling strong confidence in Sai Life's long-term performance.

The 'Follow-the-Molecule' Strategy

A key element of Sai Life Sciences' success is its 'follow-the-molecule' model. This strategy involves engaging with clients at the earliest stages of drug discovery and continuing the partnership through development, commercialisation, and lifecycle management. This integrated approach ensures deep client relationships and a steady flow of business as molecules progress through the clinical trial phases.

The company maintains a balanced service portfolio, with contract research organisation (CRO) services contributing approximately 35 percent of the business and contract development and manufacturing organisation (CDMO) services making up the remaining 65 percent. This mix allows Sai Life to secure projects early in the R&D cycle while also capturing higher-value manufacturing contracts later on, creating a sustainable growth engine.

Financial Growth and Market Position

Despite its rapid growth, Sai Life Sciences remains a relatively small player in a large addressable market. With estimated sales of around $100 million in FY25, the company has substantial room for expansion. Its historical performance highlights its execution capabilities, having delivered a sales compound annual growth rate (CAGR) of 23 percent and an impressive Ebitda CAGR of 57 percent between FY23 and FY26.

Looking ahead, Jefferies projects continued strong growth, with sales expected to grow at a 17 percent CAGR and Ebitda at a 20 percent CAGR between FY26 and FY28. The company's balance sheet is also a source of strength. It is currently net debt-neutral, and Jefferies anticipates that leverage will remain below 0.5 times, or that the company will maintain a net cash position, even with ongoing capital expenditure.

A Strong and Expanding Project Pipeline

The company's ability to consistently win new projects is a critical driver of its growth. In FY26 alone, Sai Life Sciences added seven new molecules to its pipeline. This includes three molecules in the commercial stage and four in Phase III trials. For two of the commercial molecules, Sai Life is believed to be the primary supplier, which could translate into significant revenue streams in the coming years.

Jefferies estimates that the key projects currently in the company's pipeline could address end-market sales exceeding $13 billion by the calendar year 2028. This vast market potential underscores the long-term value embedded in its development portfolio.

Strategic Advantages in a Competitive Market

Several strategic factors support Sai Life's growth trajectory. The complete exit of private equity firm TPG in 2025, which held a significant stake before the IPO, has removed a potential stock overhang. Furthermore, the company's international presence, with scientists in pharmaceutical hubs like Boston and Manchester, facilitates stronger client relationships and business development.

The broader industry trend of supply chain diversification, often termed the 'China Plus One' strategy, also benefits Indian CRDMOs like Sai Life. Global pharmaceutical companies are actively seeking reliable partners outside of China, and India is well-positioned to capture a larger share of this market due to its cost advantages and skilled workforce.

Valuation and Analyst Consensus

Despite a strong performance since its IPO, delivering returns of about 45 percent, Sai Life Sciences' stock trades at approximately 47 times its estimated FY27 earnings. This valuation is broadly in line with the sector average of 48-50 times, suggesting that its growth potential is not yet fully priced in. Jefferies sees scope for further earnings upgrades, noting that it has already raised its FY26 revenue and profit estimates by 17 percent and 30 percent, respectively, since initiating coverage.

Overall analyst sentiment is positive. The consensus price target from multiple analysts stands at around ₹1,154, with some targets reaching as high as ₹1,318. This reflects a shared belief in the company's ability to execute its strategy and capitalize on favorable industry trends.

Conclusion

Jefferies' endorsement of Sai Life Sciences highlights the company's strong fundamentals and strategic positioning within the CRDMO industry. Its integrated business model, robust financial growth, expanding pipeline, and strong balance sheet provide a solid foundation for future expansion. While risks related to execution and high valuation remain, the company appears well-equipped to navigate the competitive landscape and deliver sustained value to investors.